Child's Nervous System

, Volume 33, Issue 5, pp 849–852 | Cite as

Second re-irradiation for DIPG progression, re-considering “old strategies” with new approaches

  • Andres Morales La Madrid
  • Vicente Santa-María
  • Ofelia Cruz Martinez
  • Jaume Mora
  • Patricia Puerta Roldan
  • Antonio Guillen Quesada
  • Mariona Suñol Capella
  • Carmen de Torres Gomez-Pallete
  • Alvaro Lassaletta
  • Normand Laperriere
  • Salvador Villà
  • Eric Bouffet
Case Report
  • 246 Downloads

Abstract

Diffuse intrinsic pontine glioma (DIPG) is an aggressive infiltrative glioma for which no curative therapy is available. Radiation therapy (RT) is the only potentially effective intervention in delaying tumor progression, but only transiently. At progression, re-irradiation is gaining popularity as an effective palliative therapy. However, at second progression, exclusive symptomatic treatment is usually offered. Here we report two patients with DIPG at second progression who were treated with a second re-irradiation course with good response. Importantly, treatment was well tolerated with no irradiation associated acute toxicity identified.

Keywords

DIPG Second re-irradiation 

References

  1. 1.
    Warren KE (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2:205CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Robison NJ, Kieran MW (2014) Diffuse intrinsic pontine glioma: a reassessment. J Neuro-Oncol 119(1):7–15CrossRefGoogle Scholar
  3. 3.
    Fontanilla HP, Pinnix CC, Ketonen LM et al (2012) Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 35(1):51–57CrossRefPubMedGoogle Scholar
  4. 4.
    Massimino M, Biassoni V, Miceli R, Schiavello E 2014 Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neuroncol 305–12Google Scholar
  5. 5.
    Porkholm M, Valanne L, Lönnqvist T et al (2014) Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 61(9):1603–1609CrossRefPubMedGoogle Scholar
  6. 6.
    Buczkowicz P, Hawkins C (2015) Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol 5:147CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Puget BS, Blauwblomme T, Grill J (2012) Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? Am Soc Clin Oncol Educ Book 629–33Google Scholar
  8. 8.
    Puget S, Beccaria K, Blauwblomme T et al (2015) Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Childs Nerv Syst 31(10):1773–1780CrossRefPubMedGoogle Scholar
  9. 9.
    Buczkowicz P, Hoeman C, Rakopoulos P et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet Nature Publishing Group 46(5):451–456CrossRefGoogle Scholar
  10. 10.
    Fontebasso AM, Papillon-Cavanagh S et al (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46(5):462–466CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46(5):457–461CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Grasso CS, Tang Y, Truffaux N et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21(7):827CrossRefPubMedGoogle Scholar
  14. 14.
    Morales La Madrid A, Kieran MW, Hashizume R (2015) Future clinical trials in DIPG: bringing epigenetics to the clinic. Front Oncol 5:148CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zaghloul MS, Eldebawy E, Ahmed S et al (2014) Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 111(1):35–40CrossRefPubMedGoogle Scholar
  16. 16.
    Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neuro-Oncol. 2011 ; 104(3):773–777.Google Scholar
  17. 17.
    Janssens GO, Jansen MH, Lauwers SJ et al (2013) Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 85(2):315–320CrossRefPubMedGoogle Scholar
  18. 18.
    Wolff JE, Rytting ME, Vats TS et al (2012) Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neuro-Oncol 106(2):391–397CrossRefGoogle Scholar
  19. 19.
    Jackson S, Patay Z, Howarth R et al (2013) Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neuro-Oncol 114(3):339–344CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Andres Morales La Madrid
    • 1
    • 2
  • Vicente Santa-María
    • 2
  • Ofelia Cruz Martinez
    • 1
    • 2
  • Jaume Mora
    • 2
  • Patricia Puerta Roldan
    • 3
  • Antonio Guillen Quesada
    • 3
  • Mariona Suñol Capella
    • 4
  • Carmen de Torres Gomez-Pallete
    • 5
  • Alvaro Lassaletta
    • 6
  • Normand Laperriere
    • 7
  • Salvador Villà
    • 8
  • Eric Bouffet
    • 6
  1. 1.Pediatric Neuro-Oncology, Department of Pediatric Hematology and OncologyHospital Sant Joan de DeuBarcelonaSpain
  2. 2.Pediatric Hematology and OncologyHospital Sant Joan de DéuBarcelonaSpain
  3. 3.Pediatric NeurosurgeryHospital Sant Joan de DéuBarcelonaSpain
  4. 4.Department of PathologyHospital Sant Joan de DéuBarcelonaSpain
  5. 5.Developmental Tumor Biology LaboratoryInstitut de Recerca Pediàtrica—Hospital Sant Joan de DéuBarcelonaSpain
  6. 6.Neuro-Oncology Department, Division of Pediatric Hematology/OncologyThe Hospital for Sick ChildrenTorontoCanada
  7. 7.Department of Radiation OncologyPrincess Margaret Cancer CentreTorontoCanada
  8. 8.Department of Radiation OncologyInstitut Oncològic Teknon and Institut Català d’OncologiaBarcelonaSpain

Personalised recommendations